1 / 11

Standardizing the Evaluation of Diagnostics

Standardizing the Evaluation of Diagnostics. Jeffrey Cossman, M.D. C-Path. What is needed for Change? - a partnership. FDA. Patients. A. B. Trusted 3 rd Party. C. Multiple Companies. Research. D. E. Neutral ground. C-Path Consortia. Safety Predictive Safety Test Consortium

kiri
Télécharger la présentation

Standardizing the Evaluation of Diagnostics

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Standardizing the EvaluationofDiagnostics Jeffrey Cossman, M.D.

  2. C-Path What is needed for Change? - a partnership FDA Patients A B Trusted 3rd Party C Multiple Companies Research D E Neutral ground

  3. C-Path Consortia • Safety Predictive Safety Test Consortium • Efficacy Lung cancer - targeted therapy & companion diagnostics • Dosing Warfarin - dosing based on genotype • Major Disease Coalition Against Major Disease (CAMD) • Alzheimer’s and Parkinson’s diseases

  4. How to improve Get it right at the start • Best of class methods • Proof of reliability and performance • Standardized data submission process

  5. An ‘Underwriter’s Lab’for diagnostics • standardize clinical samples-analytes • evaluate and certify laboratory diagnostic tests • data available for submission to FDA United States Diagnostics Standards (USDS)

  6. USDS Why not standardize diagnostics? Standards setting in other industries: Drugs Semiconductors • USDS Concept • Non-profit • Associated with C-Path • Initial funding SFAz

  7. FDA view Steven Gutman,FDA Director, Office of In Vitro Diagnostic Devices “It is our belief that C-Path's EGFR project would … standardize the way studies of diagnostics for targeted therapy are performed in preparation for submissions for approval.” “The FDA and OIVD need projects like the ones C-Path is proposing to provide … a template for the validation of diagnostics (biomarkers) in guiding targeted cancer therapy.” “The future of personalized medicine rests on the ability of projects like this to be undertaken and for information and lessons learned to be broadly utilized and shared.”

  8. USDS ConceptTwo Types of Analysis • 1) Analytical evaluation performance characteristics are measured • 2) Clinical evaluation where clinical data is available. • association with a clinical condition • prediction of treatment response

  9. USDSmeeting needs • Standard sample repository • Neutral lab testing facility • Test = predicate? • Lab developed tests: evaluation • USDS oversight of …. • process, protocol and reporting

  10. USDS Value Added • Improve reporting to FDA • Compare competing products • Evidence for payer/providers/investors

  11. FAQs • Is USDS another regulatory hurdle? • No, it is not required. Additional steps are not added • How does USDS relate to NIST, CDC, CLSI, CAP,etc? • Non-duplicating, working relationship to partner on standards and methods • What if I don’t like the result? • Manufacturer can use data as it wishes • How is IP protected? • Data is confidential. Comparisons are voluntary. • How will reference standards be maintained? • To be determined on case by case basis

More Related